Eribulin, marketed as HALAVEN, is a synthetic analog of a compound derived from a marine sponge and belongs to a class of agents known as non-taxane microtubule inhibitors. Its primary antimitotic mechanism involves suppression of microtubule growth: the drug binds to the ends of microtubules, terminates protofilament elongation, and induces lattice defects that promote microtubule catastrophes, ultimately blocking cell division. But eribulin also exerts effects that have nothing to do with mitosis. Preclinical work has shown that it remodels tumor vasculature and reverses epithelial-to-mesenchymal transition, the cellular program through which cancer cells acquire migratory, invasive and therapy-resistant traits. This dual pharmacology is one reason researchers have been particularly interested in how eribulin interacts with CTCs, which often display mesenchymal characteristics.

The DETECT IVb trial was embedded in the larger DETECT study program, an unusual enterprise that screens women with metastatic breast cancer for CTCs and uses both the number and the molecular phenotype of those cells to guide treatment selection. For the IVb arm, patients whose primary tumors were HER2-negative and whose circulating tumor cells also tested HER2-negative were eligible. Most participants, 75.2 percent, had hormone receptor-positive disease and an indication for chemotherapy, while 20.2 percent had triple-negative tumors. Enrollment ran from March 2015 to October 2019, terminating prematurely because of a slow recruitment rate: instead of the planned 120 patients, 109 were registered. Each patient provided 7.5 milliliter blood samples analyzed on the CellSearch platform, the only CTC detection technology approved by regulatory authorities for prognostic use in metastatic breast cancer.

The efficacy results place eribulin squarely within expectations for advanced breast cancer. Median progression-free survival was 4.6 months, with a 95 percent confidence interval of 3.3 to 6.0 months, and median overall survival reached 13.4 months. One-year survival stood at 53.4 percent. These figures align closely with the pivotal EMBRACE phase III trial, where heavily pretreated patients on eribulin achieved a median PFS of 3.7 months and overall survival of 13.1 months, and with the phase 301 study of first- and second-line use, which reported a PFS of 4.1 and overall survival of 15.9 months. The slightly shorter survival in DETECT IVb likely reflects the design of the cohort itself: every patient entered the study with detectable CTCs, a feature that independently marks aggressive disease. In other words, even in a deliberately enriched high-risk population, eribulin delivered outcomes comparable to those seen in broader trial populations.

Safety data offered no surprises. Nearly all patients, 96.3 percent, experienced at least one adverse event, and 67 percent had at least one event of grade 3 to 5 severity. The most common toxicities of any grade were fatigue, affecting 54.1 percent of patients, alopecia at 46.8 percent, peripheral sensory neuropathy at 34.9 percent, nausea, neutropenia and constipation. Clinically significant hematologic toxicity was the dominant concern: grade 3 or higher neutropenia occurred in 21.1 percent and leukopenia in 15.6 percent of patients, rates essentially identical to those recorded in EMBRACE and the 301 study. Four patients developed febrile leukopenia, again within the range of prior trials. Peripheral neuropathy, a signature toxicity of microtubule inhibitors, appeared at a rate comparable to EMBRACE, and the authors note evidence from the prospective IRENE study suggesting that many of these events represent worsening of pre-existing taxane-related neuropathy rather than newly induced nerve damage. Only 8.3 percent of patients stopped treatment because of toxicity, and no unexpected safety signals emerged.

The heart of the trial, however, lies in its biomarker analyses. At baseline, the median CTC count was five cells per 7.5 milliliters of blood, the very threshold that has long divided metastatic breast cancer into aggressive and indolent categories. Sixty-two of the enrolled patients carried five or more CTCs. Consistent with decades of prior evidence, baseline CTC burden remained an independent prognostic factor: in multivariable Cox regression models adjusting for treatment line, metastasis-free interval, metastatic site, tumor subtype and age, patients with five or more CTCs faced a 63 percent higher risk of progression and more than double the risk of death compared with those carrying one to four cells. Adding baseline CTC status significantly improved the fit of the statistical models for both survival endpoints, reinforcing the cell count’s credential as a prognostic marker.

What happened to those counts during treatment proved even more telling. At the first on-treatment follow-up, performed at least 21 days after enrollment and typically around the second or third chemotherapy cycle, 34.7 percent of the 75 evaluable patients had cleared their CTCs entirely. Those who did lived significantly longer without progression: median PFS of 5.7 months versus 2.9 months among patients whose blood still harbored cancer cells. In adjusted multivariable analysis, complete CTC clearance at the first follow-up was significantly associated with improved PFS, with a hazard ratio of 0.56. Using the five-cell threshold rather than complete clearance produced even stronger signals: patients with fewer than five CTCs had significantly better PFS and significantly better overall survival, with a hazard ratio of 0.45 for death. The researchers repeated the analyses restricted to patients assessed within the first 84 days to rule out timing-related bias, and the conclusions held firm.

CTC dynamics measured at the end of treatment pointed in the same direction. Among the 39 patients assessed at that point, the 23.1 percent who had achieved clearance showed a median PFS of 13.4 months compared with 5.4 months for those who remained CTC-positive, a highly significant difference. Overall survival showed a favorable but statistically non-significant trend. Notably, in 72 percent of patients with serial measurements, CTC counts fell during the first weeks of eribulin therapy, with a median drop of five cells, a pattern consistent with an on-treatment biomarker that tracks pharmacodynamic response. The authors are careful to frame these findings as exploratory and hypothesis-generating rather than confirmatory. The single-arm design precludes definitive efficacy claims, missing follow-up samples may introduce so-called guarantee-time bias, and only enumeration, not molecular characterization, was performed longitudinally.

The broader context of CTC-guided therapy remains contested. While the French STIC CTC trial suggested that CTC-driven treatment choices might benefit patients with hormone receptor-positive, HER2-negative disease, both the American SWOG S0500 trial and the French CirCe01 trial failed to show a survival advantage from switching therapy early in patients whose CTCs persisted despite chemotherapy. Those negative results suggest that counting cells alone may not suffice to direct clinical decisions. The DETECT IVb findings hint at a way forward: combining longitudinal enumeration with deeper biological characterization. Earlier work from the same research group showed that accumulation of the DNA repair protein 53BP1 in CTCs identifies chemotherapy-responsive metastatic breast cancer patients, and preclinical studies indicate that eribulin induces mesenchymal-to-epithelial transition, potentially stripping CTCs of their most dangerous properties. Integrating quantitative dynamics with markers of DNA damage response, EMT status and HER2 expression on CTCs could yield a composite biomarker capable of predicting eribulin responsiveness before radiographic evaluation, roughly 12 weeks into therapy, is even possible.

For patients with HER2-negative metastatic breast cancer, a disease that remains incurable and is managed through sequential lines of therapy, the practical implications are twofold. First, the trial affirms eribulin as a safe and clinically meaningful option across treatment lines, including in a population deliberately enriched for poor prognosis. Second, it strengthens the case that a blood test repeated at the second or third cycle of chemotherapy can identify, weeks earlier than imaging, which patients are benefiting and which may need a change of strategy. The authors call for prospective, biomarker-driven interventional trials to determine whether acting on early CTC changes can actually extend survival. If those trials succeed, the humble enumeration of tumor cells in a vial of blood could evolve from a prognostic curiosity into a genuine decision-making tool in the clinic.

Subject of Research: Phase II trial of eribulin chemotherapy with circulating tumor cell monitoring in HER2-negative metastatic breast cancer

Article Title: Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer – results from the phase II DETECT IVb trial

Article References: Schochter, F., Friedl, T., Schäffler, H., Meier-Stiegen, F., Pfister, K., Riethdorf, S., Wiesmüller, L., Neubauer, H., Müller, L., Wimberger, P., Fasching, P., Lorenz, R., Hempel, T., Heublein, S., Hartkopf, A., Pantel, K., Rack, B., Müller, V., Fehm, T., … Cieslik, J. (2026). Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer – results from the phase II DETECT IVb trial. Breast Cancer Research and Treatment, 219(3), Article 12. https://doi.org/10.1007/s10549-026-08069-2

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08069-2

Keywords: eribulin, metastatic breast cancer, circulating tumor cells, CTC clearance, HER2-negative, DETECT IVb, phase II trial, CellSearch, progression-free survival, chemotherapy biomarker, epithelial-to-mesenchymal transition, drug safety